FDA Inspection 1251100 — Louise Taber, MD
The FDA completed an inspection of Louise Taber, MD on September 26, 2024 in Phoenix, AZ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 26, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Phoenix, AZ (United States)
Additional Details
Clinical Investigator (CI)